Protara Therapeutics (TARA) Liabilities and Shareholders Equity (2013 - 2026)

Protara Therapeutics (TARA) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $191.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 13.86% year-over-year to $191.9 million; the TTM figure through Mar 2026 stood at $703.0 million (up 28.81% YoY), while the FY2025 annual figure was $209.5 million, up 15.44% from the prior year.
• Liabilities and Shareholders Equity slipped to $191.9 million in Q1 2026 per TARA's latest filing, from $209.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $209.5 million in Q4 2025 and bottomed at $68.1 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $133.2 million across 5 years, with a median of $144.6 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 40.46% — and 2025, when it surged 147.39%.
• Protara Therapeutics' Liabilities and Shareholders Equity stood at $113.3 million in 2022, then slumped by 30.31% to $79.0 million in 2023, then soared by 129.82% to $181.5 million in 2024, then rose by 15.44% to $209.5 million in 2025, then declined by 8.38% to $191.9 million in 2026.
• Business Quant data shows TARA's Liabilities and Shareholders Equity at $191.9 million in Q1 2026, $209.5 million in Q4 2025, and $144.6 million in Q3 2025.